Craig Gidney is largely unknown outside of quantum computing, but his pioneering work on quantum circuits could have huge ...

Find out why the results may temper claims that recursive self-improvement is on the horizon. —Michelle Kim This summer has ...

Forecasts of explosive AI progress predict that what researchers call recursive self-improvement is on the horizon.  But a new study suggests that it might take a while for us to get there. The ...

Recursion Pharmaceuticals (NASDAQ:RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and ...

Health Discovery Corp. research and ratings by Barron's. View HDVY revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Recursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense ...

Recursion Pharmaceuticals is a drugmaker that relies on artificial intelligence (AI) to go from discovery to the market. The company is betting that its approach can succeed where other breakthroughs ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

Forbes contributors publish independent expert analyses and insights. Dr. Lance B. Eliot is a world-renowned AI scientist and consultant. In today’s column, I examine the belief that AI will ...

The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

Salt Lake City, UT, May 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the ...